Apatinib vs Ramucirumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: VEGFR2 · full Non-Small Cell Lung Cancer pipeline
Apatinib
Marketed by Jiangsu Hengrui Pharmaceuticals under a licence from Advenchen Laboratories
NCT02332512 · Phase 3 · status unknown
This is a randomized, placebo-controlled trial with full blinding of participants, care providers, and assessors, using overall survival, a hard clinical endpoint, as its primary measure. Results have not yet been posted, so whether apatinib extended survival compared with placebo is not yet known.
Next expected readout: February 2027 · NCT07031154 (registry estimate)
Reported efficacy
Progression free survival (8 weeks): Primary (PFS): median 4.7 vs 1.9 months, apatinib vs placebo, significantly improved; ORR 12.2% vs 0%; DCR 69% vs 24%. (met)
Result source: NCT01270386
Ramucirumab
Marketed by Eli Lilly
NCT01168973 · Phase 3 · completed
This large randomized, double-blind, placebo-controlled trial assigned 628 participants to ramucirumab plus docetaxel and 625 to placebo plus docetaxel, with overall survival as a hard clinical primary endpoint. The published primary analysis met its endpoint: median overall survival 10.5 vs 9.1 months (hazard ratio 0.86, 95% CI 0.75-0.98; p=0.023).
Next expected readout: December 2026 · NCT03909334 (registry estimate)
Reported efficacy
Overall survival (From date of randomization to date of death due to any cause, assessed up to 3 years): Pragmatica-Lung (NCT05633602), primary endpoint overall survival: ramucirumab plus pembrolizumab median OS 10.1 months vs SOC 10.0 months; HR 1.04 (95% CI 0.88-1.22); p=.66. (missed)
Result source: NCT05633602
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Apatinib | Ramucirumab |
|---|---|---|
| PFS, median | —Not reported | 4.5 vs 3+1.5 vs placeboNCT0116897315 other results
|
| OS, median | —Not reported | 10.5 vs 9.1+1.4 vs placeboNCT011689736 other results
|
| ORR | 16.7%bNCT03083041 | 22.9% vs 13.6%+9.3 vs placeboNCT011689739 other results
|
| Duration of response, median | —Not reported | 12.9 vs 5.6vs Standard of Care (Inv. Choice)NCT039714744 other results
|
PFS, median
- Apatinib
- —Not reported
- Ramucirumab
- 4.5 vs 3+1.5 vs placeboNCT01168973
15 other results
- 5.2 vs 4.2 NCT01703091
- 7.2 vs 5.6 NCT01160744
- 5.6 vs 5.6 NCT01160744
- 8.2 NCT02730247
- 4.5 vs 5.2 NCT03971474
- 1.6 NCT02079636
- 5.5 NCT02079636
- 1.9 NCT02079636
- 4.1 NCT02079636
- 4.8 NCT02079636
- 7.8 NCT00735696
- 1.6 NCT02082210
- 5.4 NCT02082210
- 2.9 NCT02082210
- 11.0 NCT02789345
OS, median
- Apatinib
- —Not reported
- Ramucirumab
- 10.5 vs 9.1+1.4 vs placeboNCT01168973
6 other results
- 14.5 vs 11.6 NCT03971474
- 15.2 vs 14.7 NCT01703091
- 13.9 vs 10.4 NCT01160744
- 10.4 vs 10.4 NCT01160744
- 16.9 NCT00735696
- 7.4 NCT02730247
ORR
- Apatinib
- 16.7%bNCT03083041
- Ramucirumab
- 22.9% vs 13.6%+9.3 vs placeboNCT01168973
9 other results
- 6.3% NCT02082210
- 6.7% NCT02082210
- 0% NCT02082210
- 28.9% vs 18.5% NCT01703091
- 22% vs 28% NCT03971474
- 49.3% vs 38% NCT01160744
- 46.5% vs 38% NCT01160744
- 55% NCT00735696
- 76% NCT02789345
Duration of response, median
- Apatinib
- —Not reported
- Ramucirumab
- 12.9 vs 5.6vs Standard of Care (Inv. Choice)NCT03971474
4 other results
- 5.5 vs 4.5 NCT01160744
- 4.3 vs 4.5 NCT01160744
- 5.5 NCT00735696
- 13.4 NCT02789345
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. Apatinib: 4 of 5 rows · Ramucirumab: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Apatinib | Ramucirumab |
|---|---|---|
| ORR responder rate · % of participants No placebo or comparator arm | 16.7% (n=12)375 mga,b NCT03083041 · Phase 2 · registry result, not featured evidence · combination | 55% (n=40)a,b NCT00735696 · Phase 2 · registry result, not featured evidence · combination 4 other source trials6.3% (n=16) NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination 6.7% (n=45) NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination 0% (n=15) NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination 76% (n=25) NCT02789345 · Phase 1 · registry result, not featured evidence · combination |
| Dropout rate | 91.7%375 mgc NCT03083041 · Phase 2 · registry result, not featured evidence · combination show 1 more result—250 mg NCT03083041 · Phase 2 · registry result, not featured evidence · combination | 97.6%d NCT01168973 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 show 28 more resultsn/a: no completion milestone NCT03971474 · Phase 2 · registry result, not featured evidence · combination 0% NCT02730247 · Phase 2 · registry result, not featured evidence · combination 5.6%Ram + Gem + Carb or Cis (Squamous) NCT01160744 · Phase 2 · registry result, not featured evidence · combination 7.2%Ram + Pem + Carb or Cis (Non-Squam NCT01160744 · Phase 2 · registry result, not featured evidence · combination — NCT01703091 · Phase 2 · registry result, not featured evidence · combination 4.9% NCT00735696 · Phase 2 · registry result, not featured evidence · combination 18.8%Part B - Gastric NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination 13.3%Part B - HCC NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination 20%Part B - RCC NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination 100%Arm A: Ramucirumab + Osimertinib NCT02789345 · Phase 1 · registry result, not featured evidence · combination 77.3%Cohort A: Ramucirumab + Osimertini NCT02789345 · Phase 1 · registry result, not featured evidence · combination 13.3%200 mg abemaciclib + 500 mg/m^2 pemetrexed NCT02079636 · Phase 1 · registry result, not featured evidence · combination 57.1%200 mg abemaciclib + 1250 mg/m^2 gemcitabine NCT02079636 · Phase 1 · registry result, not featured evidence · combination —200 mg abemaciclib + 10 mg/kg ramucirumab on Day 1 NCT02079636 · Phase 1 · registry result, not featured evidence · combination 31.6%200 mg abemaciclib + 10 mg/kg ramucirumab on Day 1 NCT02079636 · Phase 1 · registry result, not featured evidence · combination 33.3%200 mg abemaciclib + 150 mg LY3023414 NCT02079636 · Phase 1 · registry result, not featured evidence · combination —150 mg abemaciclib + 500 mg/m^2 pemetrexed NCT02079636 · Phase 1 · registry result, not featured evidence · combination 0%150 mg abemaciclib + 1250 mg/m^2 gemcitabine NCT02079636 · Phase 1 · registry result, not featured evidence · combination —150 mg abemaciclib + 1250 mg/m^2 gemcitabine NCT02079636 · Phase 1 · registry result, not featured evidence · combination —150 mg abemaciclib + 10 mg/kg ramucirumab on Day 1 NCT02079636 · Phase 1 · registry result, not featured evidence · combination 25%150 mg abemaciclib + 10 mg/kg ramucirumab on Days 1 and 8 NCT02079636 · Phase 1 · registry result, not featured evidence · combination 8.3%150 mg abemaciclib + 8 mg/kg ramucirumab on Days 1 and 8 NCT02079636 · Phase 1 · registry result, not featured evidence · combination 33.3%150 mg abemaciclib + 100 mg LY3023414 NCT02079636 · Phase 1 · registry result, not featured evidence · combination 20%150 mg abemaciclib + 150 mg LY3023414 NCT02079636 · Phase 1 · registry result, not featured evidence · combination 37.5%150 mg abemaciclib + 200 mg LY3023414 NCT02079636 · Phase 1 · registry result, not featured evidence · combination 29.4%150 mg abemaciclib + 200 mg pembrolizumab NCT02079636 · Phase 1 · registry result, not featured evidence · combination 0%100 mg abemaciclib + 100 mg LY3023414 NCT02079636 · Phase 1 · registry result, not featured evidence · combination 0%100 mg abemaciclib + 200 mg pembrolizumab NCT02079636 · Phase 1 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —375 mgc NCT03083041 · Phase 2 · registry result, not featured evidence · combination show 1 more result—250 mg NCT03083041 · Phase 2 · registry result, not featured evidence · combination | 15%d NCT01168973 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 show 28 more results11.6% NCT03971474 · Phase 2 · registry result, not featured evidence · combination — NCT02730247 · Phase 2 · registry result, not featured evidence · combination —Ram + Gem + Carb or Cis (Squamous) NCT01160744 · Phase 2 · registry result, not featured evidence · combination —Ram + Pem + Carb or Cis (Non-Squam NCT01160744 · Phase 2 · registry result, not featured evidence · combination — NCT01703091 · Phase 2 · registry result, not featured evidence · combination — NCT00735696 · Phase 2 · registry result, not featured evidence · combination —Part B - Gastric NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination —Part B - HCC NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination —Part B - RCC NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination 0%Arm A: Ramucirumab + Osimertinib NCT02789345 · Phase 1 · registry result, not featured evidence · combination 4.5%Cohort A: Ramucirumab + Osimertini NCT02789345 · Phase 1 · registry result, not featured evidence · combination 6.7%200 mg abemaciclib + 500 mg/m^2 pemetrexed NCT02079636 · Phase 1 · registry result, not featured evidence · combination 4.8%200 mg abemaciclib + 1250 mg/m^2 gemcitabine NCT02079636 · Phase 1 · registry result, not featured evidence · combination —200 mg abemaciclib + 10 mg/kg ramucirumab on Day 1 NCT02079636 · Phase 1 · registry result, not featured evidence · combination 10.5%200 mg abemaciclib + 10 mg/kg ramucirumab on Day 1 NCT02079636 · Phase 1 · registry result, not featured evidence · combination 0%200 mg abemaciclib + 150 mg LY3023414 NCT02079636 · Phase 1 · registry result, not featured evidence · combination —150 mg abemaciclib + 500 mg/m^2 pemetrexed NCT02079636 · Phase 1 · registry result, not featured evidence · combination 0%150 mg abemaciclib + 1250 mg/m^2 gemcitabine NCT02079636 · Phase 1 · registry result, not featured evidence · combination —150 mg abemaciclib + 1250 mg/m^2 gemcitabine NCT02079636 · Phase 1 · registry result, not featured evidence · combination —150 mg abemaciclib + 10 mg/kg ramucirumab on Day 1 NCT02079636 · Phase 1 · registry result, not featured evidence · combination 0%150 mg abemaciclib + 10 mg/kg ramucirumab on Days 1 and 8 NCT02079636 · Phase 1 · registry result, not featured evidence · combination 0%150 mg abemaciclib + 8 mg/kg ramucirumab on Days 1 and 8 NCT02079636 · Phase 1 · registry result, not featured evidence · combination 0%150 mg abemaciclib + 100 mg LY3023414 NCT02079636 · Phase 1 · registry result, not featured evidence · combination 0%150 mg abemaciclib + 150 mg LY3023414 NCT02079636 · Phase 1 · registry result, not featured evidence · combination 0%150 mg abemaciclib + 200 mg LY3023414 NCT02079636 · Phase 1 · registry result, not featured evidence · combination 0%150 mg abemaciclib + 200 mg pembrolizumab NCT02079636 · Phase 1 · registry result, not featured evidence · combination 0%100 mg abemaciclib + 100 mg LY3023414 NCT02079636 · Phase 1 · registry result, not featured evidence · combination 0%100 mg abemaciclib + 200 mg pembrolizumab NCT02079636 · Phase 1 · registry result, not featured evidence · combination |
| Serious AEs | 58.3%375 mgc NCT03083041 · Phase 2 · registry result, not featured evidence · combination show 1 more result56.6%250 mg NCT03083041 · Phase 2 · registry result, not featured evidence · combination | 45.3%d NCT01168973 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 show 28 more results40.6% NCT03971474 · Phase 2 · registry result, not featured evidence · combination 100% NCT02730247 · Phase 2 · registry result, not featured evidence · combination 54.9%Ram + Gem + Carb or Cis (Squamous) NCT01160744 · Phase 2 · registry result, not featured evidence · combination 65.7%Ram + Pem + Carb or Cis (Non-Squam NCT01160744 · Phase 2 · registry result, not featured evidence · combination 31.9% NCT01703091 · Phase 2 · registry result, not featured evidence · combination 47.5% NCT00735696 · Phase 2 · registry result, not featured evidence · combination 25%Part B - Gastric NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination 42.2%Part B - HCC NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination 33.3%Part B - RCC NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination 33.3%Arm A: Ramucirumab + Osimertinib NCT02789345 · Phase 1 · registry result, not featured evidence · combination 36.4%Cohort A: Ramucirumab + Osimertini NCT02789345 · Phase 1 · registry result, not featured evidence · combination 53.3%200 mg abemaciclib + 500 mg/m^2 pemetrexed NCT02079636 · Phase 1 · registry result, not featured evidence · combination 47.6%200 mg abemaciclib + 1250 mg/m^2 gemcitabine NCT02079636 · Phase 1 · registry result, not featured evidence · combination 63.2%200 mg abemaciclib + 10 mg/kg ramucirumab on Day 1 NCT02079636 · Phase 1 · registry result, not featured evidence · combination —200 mg abemaciclib + 10 mg/kg ramucirumab on Day 1 NCT02079636 · Phase 1 · registry result, not featured evidence · combination 0%200 mg abemaciclib + 150 mg LY3023414 NCT02079636 · Phase 1 · registry result, not featured evidence · combination 50%150 mg abemaciclib + 500 mg/m^2 pemetrexed NCT02079636 · Phase 1 · registry result, not featured evidence · combination —150 mg abemaciclib + 1250 mg/m^2 gemcitabine NCT02079636 · Phase 1 · registry result, not featured evidence · combination 33.3%150 mg abemaciclib + 1250 mg/m^2 gemcitabine NCT02079636 · Phase 1 · registry result, not featured evidence · combination 75%150 mg abemaciclib + 10 mg/kg ramucirumab on Day 1 NCT02079636 · Phase 1 · registry result, not featured evidence · combination 75%150 mg abemaciclib + 10 mg/kg ramucirumab on Days 1 and 8 NCT02079636 · Phase 1 · registry result, not featured evidence · combination 25%150 mg abemaciclib + 8 mg/kg ramucirumab on Days 1 and 8 NCT02079636 · Phase 1 · registry result, not featured evidence · combination 22.2%150 mg abemaciclib + 100 mg LY3023414 NCT02079636 · Phase 1 · registry result, not featured evidence · combination 30%150 mg abemaciclib + 150 mg LY3023414 NCT02079636 · Phase 1 · registry result, not featured evidence · combination 50%150 mg abemaciclib + 200 mg LY3023414 NCT02079636 · Phase 1 · registry result, not featured evidence · combination 52.9%150 mg abemaciclib + 200 mg pembrolizumab NCT02079636 · Phase 1 · registry result, not featured evidence · combination 33.3%100 mg abemaciclib + 100 mg LY3023414 NCT02079636 · Phase 1 · registry result, not featured evidence · combination 0%100 mg abemaciclib + 200 mg pembrolizumab NCT02079636 · Phase 1 · registry result, not featured evidence · combination |
| Most frequent reported AEs | 375 mgc rash 91.7% hypertension 83.3% decreased appetite 75% NCT03083041 · Phase 2 · registry result, not featured evidence · combination show 1 more result250 mg hypertension 63.6% proteinuria 63.1% aspartate aminotransferase increased 53.5% NCT03083041 · Phase 2 · registry result, not featured evidence · combination | d fatigue 45.8% (placebo 42.1%) neutropenia 36.4% (placebo 30.4%) diarrhoea 31.9% (placebo 28.3%) NCT01168973 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 show 26 more resultsfatigue 56.5% hypoalbuminemia 44.9% hyponatremia 39.1% NCT03971474 · Phase 2 · registry result, not featured evidence · combination anemia 85.7% hyponatremia 85.7% fatigue 71.4% NCT02730247 · Phase 2 · registry result, not featured evidence · combination neutropenia 73.2% fatigue 54.9% anaemia 53.5% NCT01160744 · Phase 2 · registry result, not featured evidence · combination fatigue 65.7% nausea 52.2% anaemia 47.8% NCT01160744 · Phase 2 · registry result, not featured evidence · combination neutrophil count decreased 77.7% (placebo 70.4%) white blood cell count decreased 77.7% (placebo 69.4%) alopecia 67% (placebo 62.2%) NCT01703091 · Phase 2 · registry result, not featured evidence · combination fatigue 72.5% neuropathy peripheral 67.5% alopecia 57.5% NCT00735696 · Phase 2 · registry result, not featured evidence · combination fatigue 68.8% decreased appetite 50% nausea 50% NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination oedema peripheral 57.8% fatigue 55.6% hypoalbuminaemia 28.9% NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination dyspnoea 53.3% fatigue 40% menorrhagia 33.3% NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination cough 100% diarrhoea 100% arthralgia 66.7% NCT02789345 · Phase 1 · registry result, not featured evidence · combination diarrhoea 63.6% hypertension 63.6% decreased appetite 40.9% NCT02789345 · Phase 1 · registry result, not featured evidence · combination 200 mg abemaciclib + 500 mg/m^2 pemetrexed diarrhoea 93.3% anaemia 80% fatigue 80% NCT02079636 · Phase 1 · registry result, not featured evidence · combination 200 mg abemaciclib + 1250 mg/m^2 gemcitabine fatigue 81% diarrhoea 61.9% nausea 61.9% NCT02079636 · Phase 1 · registry result, not featured evidence · combination 200 mg abemaciclib + 10 mg/kg ramucirumab on Day 1 diarrhoea 73.7% fatigue 63.2% nausea 63.2% NCT02079636 · Phase 1 · registry result, not featured evidence · combination 200 mg abemaciclib + 150 mg LY3023414 nausea 50% decreased appetite 33.3% fatigue 33.3% NCT02079636 · Phase 1 · registry result, not featured evidence · combination 150 mg abemaciclib + 500 mg/m^2 pemetrexed anaemia 75% blood creatinine increased 62.5% fatigue 62.5% NCT02079636 · Phase 1 · registry result, not featured evidence · combination 150 mg abemaciclib + 1250 mg/m^2 gemcitabine nausea 100% anxiety 66.7% dry skin 66.7% NCT02079636 · Phase 1 · registry result, not featured evidence · combination 150 mg abemaciclib + 10 mg/kg ramucirumab on Day 1 diarrhoea 50% fatigue 50% alanine aminotransferase increased 25% NCT02079636 · Phase 1 · registry result, not featured evidence · combination 150 mg abemaciclib + 10 mg/kg ramucirumab on Days 1 and 8 asthenia 75% decreased appetite 75% diarrhoea 50% NCT02079636 · Phase 1 · registry result, not featured evidence · combination 150 mg abemaciclib + 8 mg/kg ramucirumab on Days 1 and 8 diarrhoea 83.3% decreased appetite 50% nausea 50% NCT02079636 · Phase 1 · registry result, not featured evidence · combination 150 mg abemaciclib + 100 mg LY3023414 diarrhoea 66.7% nausea 55.6% fatigue 44.4% NCT02079636 · Phase 1 · registry result, not featured evidence · combination 150 mg abemaciclib + 150 mg LY3023414 diarrhoea 90% vomiting 70% nausea 60% NCT02079636 · Phase 1 · registry result, not featured evidence · combination 150 mg abemaciclib + 200 mg LY3023414 diarrhoea 75% vomiting 75% decreased appetite 62.5% NCT02079636 · Phase 1 · registry result, not featured evidence · combination 150 mg abemaciclib + 200 mg pembrolizumab fatigue 70.6% diarrhoea 58.8% decreased appetite 52.9% NCT02079636 · Phase 1 · registry result, not featured evidence · combination 100 mg abemaciclib + 100 mg LY3023414 anaemia 66.7% diarrhoea 66.7% fatigue 66.7% NCT02079636 · Phase 1 · registry result, not featured evidence · combination 100 mg abemaciclib + 200 mg pembrolizumab fatigue 100% anaemia 66.7% proteinuria 66.7% NCT02079636 · Phase 1 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bThe assessment timepoint is not available for both results.
- cPopulation comparability has not been reviewed for these studies.
- dPopulation comparability has not been reviewed for 28 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Ramucirumab
show 4 more results
show 4 more results
show 4 more results
show 4 more results
show 2 more results
show 10 more results
show 2 more results
+ 18 further endpoints in the CSV export.
Hepatocellular Carcinoma
Shared mechanism: VEGFR2 · full Hepatocellular Carcinoma pipeline
Apatinib
Marketed by Jiangsu Hengrui Pharmaceuticals under a licence from Advenchen Laboratories
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT06454578 (registry estimate)
No aligned efficacy figure on record for this race.
Ramucirumab
Marketed by Eli Lilly
NCT02435433 · Phase 3 · completed
The main comparison randomized 292 participants (197 ramucirumab and 95 placebo) and was double-blind and placebo-controlled, with overall survival as the primary clinical endpoint; overall survival favored ramucirumab and met statistical significance (p=0.0199). The record enrolled 399 participants overall, including additional open-label cohorts, but no primary-endpoint power calculation is reported in the available sources, so the evidence is considered moderate rather than strong.
Reported efficacy
Overall Survival (OS) (From Date of Randomization to Death from Any Cause (Up to 28 Months)): Overall Survival (OS) (From Date of Randomization to Death from Any Cause (Up to 28 Months)): Ramucirumab + Best Supportive Care (BSC) 8.51 Months (95% CI 7 to 10.58) | Placebo + BSC 7.29 Months (95% CI 5.42 to 9.07) (met)
Result source: NCT02435433
Results for Hepatocellular Carcinoma
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Apatinib: registry results are on file for Hepatocellular Carcinoma, but their comparison mappings are not yet available.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Ramucirumab
show 2 more results
show 2 more results
show 2 more results
Available safety results
Ramucirumab
| Dropout rate | 18.8%Part B - Gastric NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination show 2 more results13.3%Part B - HCC NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination 20%Part B - RCC NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination |
|---|---|
| Discontinued due to AEs | —Part B - Gastric NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination show 2 more results—Part B - HCC NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination —Part B - RCC NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination |
| Serious AEs | 25%Part B - Gastric NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination show 2 more results42.2%Part B - HCC NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination 33.3%Part B - RCC NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | fatigue 68.8% decreased appetite 50% nausea 50% NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination show 2 more resultsoedema peripheral 57.8% fatigue 55.6% hypoalbuminaemia 28.9% NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination dyspnoea 53.3% fatigue 40% menorrhagia 33.3% NCT02082210 · Phase 1/2 · registry result, not featured evidence · combination |
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Apatinib's landscape · Ramucirumab's landscape